Introducing GlucodOX®— the only patented guggul-based nutraceutical for stimulating AMPK to support metabolic health and wellness.
Extends your “healthspan” by enhancing the body’s response to cellular and metabolic stress:
Most guggulsterones support normal lipid (cholesterol) and glucose (diabetes) metabolism. By stimulating AMPK, the patented formulation in GlucodOX takes guggulsterones further, adding longevity-promoting mechanisms much like metformin.
Gave me lots of energy to get through the day! I’m psyched I found GlucodOX, keep it coming!
I’ve had difficulty lowering my fasting blood sugar, and I don’t want to be on Metformin or insulin. I’ve been trying different products with ok results at best, and even when on these products and fasting for 8 hours 160 is about the lowest I could get my blood sugar. After taking Glucodox only twice, one capsule each time, my blood sugar was at 125 and that was only at 5 hours of fasting.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. References: 1. Data on file. Nutent Therapeutics. 2. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005;25(10):2020-2030. 3. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14:539-549. 4. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006;116:1776-1783. 5. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025-1078. 6. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase–development of the energy sensor concept. J Physiol. 2006;574:7-15. 7. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146(3):984-991. 8. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signaling. J Mol Endocrinol. 2010;44:87-97. 9. Osler ME, Zierath JR. Adenosine 5’-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology. 2008;149:935-941. 10. Sharma B, Salunke R, Srivastava S, Majumder C, Roy P. Effects of guggulsterone isolated from Commiphora mukul in high fat diet induced diabetic rats. Food Chem Toxicol. 2009; 47(10):2631-2639. 11. Yang JY, Della-Fera MA, Baile CA. Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 cells. Obesity. 2008;16:16-22. 12. Rizzo G, Disante M, Mencarelli A, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006;70:1164-1173. 13. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India. 1989;37:323-328. 14. Gopal K, Saran RK, Nityanand S, et al. Clinical trial of ethyl acetate extract of gum gugulu (gugulipid) in primary hyperlipidemia. J Assoc Physicians India. 1986;34:249-251. 15. Agarwal RC, Singh SP, Saran RK, et al. Clinical trial of gugulipid–a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626-634. 16. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056-1060. 17. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296:1703-1706. 18. Salminen A, Kaarniranta K, Kauppinen A. Age-related changes in AMPK activation: role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. Ageing Res Rev. 2016;28:15-26. 19. Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11:230-241. 20. Yang JY, Della-Fera MA, Rayalam S, Ambati S, Baile CA. Enhanced pro-apoptotic and anti-adipogenic effects of genistein plus guggulsterone in 3T3-L1 adipocytes. Biofactors. 2007;30:159-169. 21. Ramachandran C, Nair SM, Quirrin K-W, Melnick, SJ. Hypolipidemic effects of a proprietary Commiphora mukul gum resin extract and medium-chain triglyceride preparation (GU-MCT810). J Ev Comp Alt Med. 2013;18(4):248-256. https://doi. org/10.1177/2156587213488601. 22. Kunnumakkara AB, Banik K, Bordoloi D, et al. Googling the guggul (commiphora and boswellia) for prevention of chronic diseases. Front Pharmacol. 2018;9:686. doi:10.3389/fphar.2018.00686. 23. Dev S. Ethnotherapeutics and modern drug development: the potential of ayurveda. Curr Sci. 1997;73(11): 909-928. www.jstor.org/stable/24101288.